TY - JOUR T1 - Diurnal variation in forced vital capacity in patients with fibrotic interstitial lung disease using home spirometry JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00054-2020 VL - 6 IS - 1 SP - 00054-2020 AU - Catharina C. Moor AU - Carlijn A.L. van den Berg AU - Lidewij S. Visser AU - Joachim G.J.V. Aerts AU - Vincent Cottin AU - Marlies S. Wijsenbeek Y1 - 2020/01/01 UR - http://openres.ersjournals.com/content/6/1/00054-2020.abstract N2 - Forced vital capacity (FVC) is used as the routine physiological measure to assess disease progression in fibrotic interstitial lung diseases (f-ILDs) [1]. New drugs are currently being investigated on top of “standard care” with antifibrotic drugs in idiopathic pulmonary fibrosis (IPF) and other f-ILD, resulting in small margins of change in FVC [2, 3]. Recently, the first trial of antifibrotic medication in patients with systemic sclerosis-associated interstitial lung disease has shown a numerically small but significant lower annualised rate of FVC decline (41 mL) in patients treated with nintedanib compared with placebo [3].This study demonstrates a diurnal variation in FVC measured with home spirometry in patients with f-ILD, with a higher FVC in the morning than in the afternoon http://bit.ly/37SQtBK ER -